Pharmicell Co.,Ltd.
Financials
Valuation Metrics
Pharmicell Co.,Ltd.'s Market Cap is ₩5682B. At end of 2025 it was ₩8719B. Ranked #405 of 2,410 in KR market (top 17%), #266 of 779 on KOSPI (top 34%), #46 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 568.24B KRW | KR#405/2,410 Sec#46/231 |
| Revenue | 135.94B KRW | KR#1,239/2,410 Sec#76/231 |
| Net Income | 46.53B KRW | KR#442/2,410 Sec#26/231 |
| Total Assets | 184.15B KRW | KR#1,371/2,410 Sec#102/231 |
| Net Assets | 143.37B KRW | KR#1,169/2,410 Sec#85/231 |
| Employees | 146 | KR#1,344/2,410 Sec#109/231 |
| Value | ||
| P/E | 12.21x | KR#990/2,410 Sec#55/231 |
| P/B | 3.96x | KR#2,216/2,410 Sec#189/231 |
| PEG | 0.10x | KR#428/2,410 Sec#21/231 |
| P/S | 4.18x | KR#2,120/2,410 Sec#143/231 |
| EV/EBITDA | 13.12x | KR#827/2,410 Sec#46/231 |
| FCF Yield | 5.91% | KR#834/2,410 Sec#43/231 |
| Profitability | ||
| ROE | 32.46% | KR#48/2,410 Sec#5/231 |
| ROA | 25.27% | KR#28/2,410 Sec#5/231 |
| Op. Margin | 32.42% | KR#45/2,410 Sec#10/231 |
| Revenue Growth | 51.28% | KR#200/2,410 Sec#26/231 |
| Earnings Growth | 124.70% | KR#349/2,410 Sec#22/231 |
| Financial Health | ||
| Debt Ratio | 28.45% | KR#549/2,410 Sec#61/231 |
| Total Debt | 25.02B KRW | KR#1,302/2,410 Sec#103/231 |
| FCF | 33.60B KRW | KR#387/2,410 Sec#22/231 |
| Cash | 15.04B KRW | KR#1,425/2,410 Sec#111/231 |
| Current Ratio | 7.15x | KR#167/2,410 Sec#37/231 |
| Net Debt/EBITDA | 0.23x | KR#635/2,410 Sec#37/231 |
| Dividend | ||
| Div. Yield | 0.53% | KR#1,272/2,410 Sec#79/231 |
| Div. Growth | 150.00% | KR#65/2,410 Sec#2/231 |
| Performance | ||
| 1Y Return | -44.20% | KR#1,848/2,410 Sec#163/231 |
| 1M Return | -23.63% | KR#2,047/2,410 Sec#207/231 |
| From 52W High | -55.22% | KR#1,396/2,410 Sec#114/231 |
| 1Y MDD | -56.74% | KR#1,253/2,410 Sec#103/231 |
| Trading | ||
| Volume | 216,205 shares | KR#211/2,410 Sec#16/231 |
| Trading Value | 2.04B KRW | KR#344/2,410 Sec#35/231 |
| Foreign Own. | 8.54% | KR#531/2,410 Sec#45/231 |
| Per Share | ||
| EPS | 776 KRW | KR#822/2,410 Sec#60/231 |
| BPS | 2,389 KRW | KR#1,990/2,410 Sec#161/231 |
Company Info
Pharmicell, established in 1968 and renamed in 2011, is a specialized biotech company listed in 1988. It operates a biomedical division, manufacturing and selling the world's first stem cell therapy, and a biochemical division, producing pharmaceutical intermediates and eco-friendly phosphorus flame retardants, in addition to stem cell banking and cosmetics businesses. The company has developed and patented technologies for anticancer immunotherapy dendritic cells and neurological disorder treatments. Pharmicell is actively pursuing innovation through technology development in areas such as mRNA vaccine raw materials and artificial blood, and is headquartered in Gangnam-gu, Seoul.